Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Rheumatology

Standard of Care: Modern Treatment for MPA

At a Glance

Treatment for Microscopic Polyangiitis (MPA) uses a two-phase approach: a 3-6 month induction phase to stop active inflammation, and a longer maintenance phase to prevent relapse. Newer medications like Avacopan help control the disease while reducing the need for high-dose steroids.

Treating Microscopic Polyangiitis (MPA) has changed significantly in the last few years. The goal is no longer just “surviving” the disease, but reaching remission (a state of no active inflammation) while using the lowest possible amount of steroids [1][2]. Because MPA is rare and complex, current guidelines strongly emphasize finding a vasculitis specialist—a doctor, usually a rheumatologist or nephrologist, who focuses specifically on these conditions [3].

The Two-Phase Treatment Strategy

Doctors approach MPA treatment in two distinct stages, similar to putting out a fire and then preventing it from restarting [3].

Phase 1: Induction (Putting Out the Fire)

This phase lasts roughly 3 to 6 months. The goal is to stop the immune system from attacking your blood vessels immediately [4].

  • For Severe/Organ-Threatening Disease: If your kidneys or lungs are involved, the standard of care is a combination of high-dose glucocorticoids (steroids like prednisone) plus either Rituximab or Cyclophosphamide [4][3].
    • A Critical Note on Cyclophosphamide: While highly effective, Cyclophosphamide is a harsh chemotherapy drug. It carries risks of bladder toxicity and infertility. Patients of childbearing age should ask about fertility preservation before starting this medication [3].
  • For Non-Organ-Threatening Disease: Treatments may be slightly less intense, often using Rituximab or Methotrexate alongside steroids [3].
  • Infection Prophylaxis: Because these medications heavily suppress your immune system, your doctor will likely prescribe a daily preventative antibiotic (such as Bactrim) to protect you from life-threatening opportunistic lung infections [3].

Phase 2: Maintenance (Keeping the Fire Out)

Once you are in remission, you will switch to maintenance therapy to prevent a relapse [5].

  • Rituximab: This is now often the preferred choice for maintenance. Research shows it is superior to older drugs like Azathioprine at keeping patients in remission over a 5-year period [5][6].
  • Duration: Maintenance typically lasts at least 18 to 24 months, though some patients may stay on it longer depending on their risk of the disease returning [7][8].

The Role of Avacopan: A “Steroid-Sparing” Breakthrough

One of the biggest recent changes in MPA care is the approval of Avacopan (Tavneos) [9].

  • How it Works: In the past, high doses of steroids were required to control the immune system, but they caused many side effects (weight gain, bone loss, infections) [10].
  • The Benefit: Avacopan targets a specific part of the immune system (the C5a receptor). In clinical trials, it was shown to be as effective as prednisone for getting patients into remission and superior for keeping them there at one year [11]. This allows doctors to use much lower doses of steroids [10][12].

Specialized Treatments for Severe Cases

In very specific, life-threatening situations, other tools may be used:

  • Plasma Exchange (PLEX): This process “cleans” the blood of harmful antibodies [13]. While not used for everyone, it may be considered if a patient has severe lung bleeding (alveolar hemorrhage) or rapidly failing kidneys [14][15].

Treatment Decision Path (Simplified)

  1. Diagnosis: Is it MPA? (Confirmed by ANCA tests and/or biopsy) [3].
  2. Severity Check: Is it organ-threatening? [3].
    • If Yes: Induction with Rituximab/Cyclophosphamide + Steroids (and potentially Avacopan) [4].
  3. Remission Goal: Achieve no active disease by 6 months [11].
  4. Maintenance: Switch to Rituximab or Azathioprine for 18+ months to prevent relapse [5][7].

Common questions in this guide

What is the goal of induction therapy for MPA?
The goal of induction therapy is to quickly stop the immune system from attacking your blood vessels. This phase usually lasts 3 to 6 months and relies on strong medications to put out the active inflammation and protect major organs.
Is Avacopan an alternative to steroids for MPA?
Avacopan is a newer medication that helps reduce the need for high doses of steroids like prednisone. By targeting a specific part of the immune system, it can effectively control the disease while minimizing harsh steroid side effects like weight loss and bone damage.
What is the difference between Rituximab and Cyclophosphamide?
Both are powerful immune-suppressing drugs used for severe MPA. While both are highly effective, Cyclophosphamide is a chemotherapy drug that carries higher risks of bladder toxicity and infertility, so it is important to discuss fertility preservation before starting it.
How long will I need to be on MPA maintenance therapy?
Once remission is achieved, maintenance therapy typically lasts at least 18 to 24 months. Some patients may need to continue treatment longer depending on their individual risk of a disease relapse.
Why do I need to take a preventative antibiotic during treatment?
Because MPA treatments heavily suppress your immune system, you are at a higher risk for serious infections. A daily preventative antibiotic helps protect you from life-threatening lung infections while your immune system is vulnerable.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my biopsy and lab results, is my MPA currently considered 'organ-threatening' or 'severe'?
  2. 2.Am I a candidate for Avacopan? If so, how quickly can we begin tapering my prednisone dose?
  3. 3.Which induction medication is better for me: Rituximab or Cyclophosphamide?
  4. 4.Are there steps I should take for fertility preservation before starting Cyclophosphamide?
  5. 5.How long do you expect me to stay on maintenance therapy once I reach remission?
  6. 6.Will you be prescribing a prophylactic antibiotic (like Bactrim) to protect me from infections?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Diagnosis and management of ANCA-associated vasculitis.

    Kronbichler A, Bajema IM, Bruchfeld A, et al.

    Lancet (London, England) 2024; (403(10427)):683-698 doi:10.1016/S0140-6736(23)01736-1.

    PMID: 38368016
  2. 2

    Recent pathogenetic insights and therapeutic advances in ANCA-associated vasculitis.

    Sagy I, Jayne DRW

    Annals of the rheumatic diseases 2026; (85(4)):588-602 doi:10.1016/j.ard.2025.11.024.

    PMID: 41469274
  3. 3

    Recommendations for the diagnosis and treatment of anti-neutrophil cytoplasmic autoantibody associated vasculitis.

    Morales E, Rúa-Figueroa I, Callejas Rubio JL, et al.

    Nefrologia 2025; (45(1)):15-58 doi:10.1016/j.nefroe.2025.01.001.

    PMID: 39855968
  4. 4

    Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of microscopic polyangiitis and granulomatosis with polyangiitis: The 2023 update - secondary publication.

    Sada KE, Nagasaka K, Kaname S, et al.

    Modern rheumatology 2024; (34(3)):559-567 doi:10.1093/mr/road081.

    PMID: 37599461
  5. 5

    Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.

    Terrier B, Pagnoux C, Perrodeau É, et al.

    Annals of the rheumatic diseases 2018; (77(8)):1150-1156 doi:10.1136/annrheumdis-2017-212768.

    PMID: 29724729
  6. 6

    Systematic review and meta-analysis for 2023 clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis.

    Watanabe R, Oshima M, Nishioka N, et al.

    Modern rheumatology 2023; (33(5)):982-989 doi:10.1093/mr/roac114.

    PMID: 36112482
  7. 7

    Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.

    Karras A, Pagnoux C, Haubitz M, et al.

    Annals of the rheumatic diseases 2017; (76(10)):1662-1668 doi:10.1136/annrheumdis-2017-211123.

    PMID: 28546260
  8. 8

    Practical Management of ANCA-Associated Vasculitis: A Clinician's Perspective.

    Stacey HL, Francis L, Smith RM, Jones RB

    Glomerular diseases 2025; (5(1)):84-102 doi:10.1159/000543159.

    PMID: 39991192
  9. 9

    Treatment With Avacopan in Patients With Respiratory Tract Manifestations of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

    Specks U, Spiera RF, Fussner LA, et al.

    ACR open rheumatology 2025; (7(1)):e11795 doi:10.1002/acr2.11795.

    PMID: 39854178
  10. 10

    Avacopan as an add-on therapy for ANCA-associated vasculitis: a pharmacological overview.

    Tesar V, Hartinger JM, Hruskova Z

    Expert review of clinical pharmacology 2024; (17(12)):1099-1113 doi:10.1080/17512433.2024.2432500.

    PMID: 39611585
  11. 11

    Avacopan for the Treatment of ANCA-Associated Vasculitis.

    Jayne DRW, Merkel PA, Schall TJ, et al.

    The New England journal of medicine 2021; (384(7)):599-609 doi:10.1056/NEJMoa2023386.

    PMID: 33596356
  12. 12

    Efficacy and safety of avacopan for treatment of patients with ANCA-associated vasculitis receiving cyclophosphamide.

    Geetha D, Neumann T, Karras A, et al.

    RMD open 2025; (11(4)) doi:10.1136/rmdopen-2025-005743.

    PMID: 41052893
  13. 13

    Plasma exchange for the management of ANCA-associated vasculitis: the con position.

    Specks U, Fussner LA, Cartin-Ceba R, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2021; (36(2)):231-236 doi:10.1093/ndt/gfaa312.

    PMID: 33374017
  14. 14

    Does plasma exchange have a role in ANCA-associated vasculitis? Viewpoint 2: plasma exchange may be useful under some circumstances.

    Odler B, Kronbichler A, Szpirt WM

    Rheumatology (Oxford, England) 2025; (64(Supplement_1)):i68-i70 doi:10.1093/rheumatology/keae612.

    PMID: 40071413
  15. 15

    Therapeutic Plasma Exchange: A Lifesaving Therapy in Case of ANCA-associated Vasculitis with Diffuse Alveolar Hemorrhage.

    Tripathi PP, Sharma RR, Chhabria B, et al.

    Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine 2021; (25(7)):828-829 doi:10.5005/jp-journals-10071-23889.

    PMID: 34316182

This page explains Microscopic Polyangiitis (MPA) treatment options for educational purposes only. Always consult your rheumatologist or nephrologist for personalized medical advice.

Get notified when new evidence is published on Microscopic polyangiitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.